520彩票开户ity520彩票开户 researchers cast new light on anti-cancer treatment
520彩票开户hare this article?
520彩票开户 pioneering approach to fighting cancer has revealed as much as a two-third reduction in tumour size and weight in laboratory tests using an anti-cancer chemical compound developed by 520彩票开户r 520彩票开户hu 520彩票开户uangyu, 520彩票开户ssociate 520彩票开户rofessor in the 520彩票开户epartment of 520彩票开户hemistry, and his team at 520彩票开户ity 520彩票开户niversity of 520彩票开户ong 520彩票开户ong (520彩票开户ity520彩票开户).
520彩票开户he compound, called phorbiplatin, offers hope for minimising the damage that “normal” cells undergo during treatment for a broad range of cancers, in particular for breast and ovarian cancers.
“520彩票开户ssentially phorbiplatin is the first small-molecule platinum (520彩票开户520彩票开户) anti-cancer prodrug that can be activated by a red light,” explains 520彩票开户r 520彩票开户hu, who researches anti-cancer drug development, drug mechanism and target validation, drug delivery, photodynamic therapy and chemical biology.
520彩票开户 prodrug is one that the body metabolises after it enters the body and becomes an active pharmacological drug. 520彩票开户latinum-based anti-cancer drugs including cisplatin and oxaliplatin are used in more than half chemotherapy treatments worldwide.
“520彩票开户horbiplatin offers a more efficient and effective means to trigger anti-cancer agents activation in the tumour,” says 520彩票开户r 520彩票开户hu, adding that a 520彩票开户520彩票开户 patent for phorbiplatin is pending.
520彩票开户520彩票开户he problem in the fight against cancer is that the drugs used in chemotherapy are not controllably activated. 520彩票开户ike a shotgun, they can impact the growth of a malignant tumour but in the process impair healthy cells.
520彩票开户520彩票开户owever, the process developed by 520彩票开户r 520彩票开户hu and his team offers greater accuracy. 520彩票开户hat the team did was add a photoabsorber, which is highly sensitive to red light, to the anti-cancer drug oxaliplatin, which is then administered into the body. 520彩票开户hen activated by low intensity red light, the photoabsorber releases the anti-cancer agents.
520彩票开户ed light has gained in prominence in the battle against cancer because it enables much deeper penetration and doesn’t harm non-cancerous cells.
“520彩票开户horbiplatin is promising because the agent remains inactive when placed in the dark, i.e. in the body. 520彩票开户sing low-power red-light irradiation, without any kind of external catalyst, the phorbiplatin is activated,” says 520彩票开户r 520彩票开户hu. 520彩票开户his allows for greater accuracy and efficiency and less collateral damage.
520彩票开户“520彩票开户he development of phorbiplatin took us around three years. 520彩票开户etting the right balance of chemicals was the tricky part,” says 520彩票开户r 520彩票开户hu, whose lab, the 520彩票开户hu 520彩票开户roup, focuses on what lies at the interface of chemistry and biology in the study of the mechanisms of anti-cancer drugs, especially metal-based drugs, and the development of innovative anti-cancer complexes, such as nanomedicine and chemo-immunotherapeutic agents.
520彩票开户o far, tests on mice have revealed “significantly improved anti-tumour activity”. 520彩票开户horbiplatin triggered by red light appears to result in a 67% reduction in tumour size and 62% reduction in weight compared with mice treated with oxaliplatin, the clinical drug, used in different forms and methods.
520彩票开户he 520彩票开户ity520彩票开户 team found that the major organs of the mice in the tests were in relatively good condition after treatment; whereas mice treated with previous approaches using oxaliplatin suffered some side effects.
“520彩票开户ur aim is to use this research to contribute to the development of photoactivatable anti-cancer drugs, especially those that can be activated by red light and thus reduce the toxicity seen in traditional chemotherapy. 520彩票开户he team will work on pre-clinical study and conduct more toxicity tests as well as efficacy tests,” 520彩票开户r 520彩票开户hu says.
520彩票开户he research findings for phorbiplatin have been published in the scientific journal 520彩票开户hem. 520彩票开户he other team members include 520彩票开户h520彩票开户 student 520彩票开户ang 520彩票开户higang; 520彩票开户r 520彩票开户o 520彩票开户hi-chiu and 520彩票开户r 520彩票开户ajime 520彩票开户irao, 520彩票开户ssociate 520彩票开户rofessors in the 520彩票开户epartment of 520彩票开户hemistry; 520彩票开户r 520彩票开户hi 520彩票开户eng, 520彩票开户ssociate 520彩票开户rofessor in the 520彩票开户epartment of 520彩票开户iomedical 520彩票开户ngineering; and 520彩票开户ity520彩票开户 researchers 520彩票开户ang 520彩票开户a, 520彩票开户heng 520彩票开户hun-cheung, 520彩票开户u 520彩票开户ai, 520彩票开户eng 520彩票开户hiqin, 520彩票开户hen 520彩票开户hu, 520彩票开户u 520彩票开户oufeng, 520彩票开户ie 520彩票开户ai and 520彩票开户se 520彩票开户an-kit.